Abstract
Although there has been substantial progress in the treatment of congestive heart failure over the last several decades, it is clear that heart failure continues to burden our aging population. As the epidemic of heart failure grows, there remains an unmistakable need for novel diagnostic and therapeutic options in its management. In this article, we review recent innovations in the management of congestive heart failure, highlighting several recent clinical trials.
MeSH terms
-
Age Factors
-
Biomarkers / blood
-
C-Reactive Protein
-
Cardiovascular Agents / classification
-
Cardiovascular Agents / therapeutic use
-
Heart Failure / diagnosis*
-
Heart Failure / drug therapy*
-
Heart Failure / physiopathology
-
Humans
-
Natriuretic Peptide, Brain / therapeutic use
-
Neurotransmitter Agents / classification
-
Neurotransmitter Agents / therapeutic use
-
Pyridines / therapeutic use
-
Thiazepines / therapeutic use
Substances
-
Biomarkers
-
Cardiovascular Agents
-
Neurotransmitter Agents
-
Pyridines
-
Thiazepines
-
Natriuretic Peptide, Brain
-
omapatrilat
-
C-Reactive Protein